Novo Nordisk A/S (NYSE:NVO) Shares Up 0.3%

Novo Nordisk A/S (NYSE:NVO)’s stock price was up 0.3% during trading on Friday . The stock traded as high as $130.16 and last traded at $128.40. Approximately 3,656,540 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 5,949,096 shares. The stock had previously closed at $128.05.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NVO shares. TD Cowen upped their price target on shares of Novo Nordisk A/S from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday, December 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, March 20th. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.25.

Novo Nordisk A/S Trading Up 0.3 %

The company’s 50 day moving average price is $121.76 and its 200 day moving average price is $104.38. The company has a market cap of $576.20 billion, a price-to-earnings ratio of 47.47, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The company had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Research analysts anticipate that Novo Nordisk A/S will post 3.35 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th will be paid a dividend of $0.664 per share. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date is Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Newbridge Financial Services Group Inc. grew its stake in Novo Nordisk A/S by 801.4% in the 4th quarter. Newbridge Financial Services Group Inc. now owns 4,390 shares of the company’s stock valued at $454,000 after buying an additional 3,903 shares during the last quarter. HighPoint Advisor Group LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $1,876,000. PNC Financial Services Group Inc. grew its stake in Novo Nordisk A/S by 3.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 647,614 shares of the company’s stock valued at $66,996,000 after buying an additional 22,669 shares during the last quarter. M3 Advisory Group LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $210,000. Finally, Walden Wealth Partners LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $445,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.